BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

525 related articles for article (PubMed ID: 25857817)

  • 21. Molecular Profile of Subungual Melanoma: A MelaNostrum Consortium Study of 68 Cases Reporting BRAF, NRAS, KIT, and TERT Promoter Status.
    Millan-Esteban D; García-Casado Z; Macià A; de la Rosa I; Torrecilla-Vall-Llossera C; Penin RM; Manrique-Silva E; Pellegrini S; Biasin MR; Rizzolo P; Gavillero A; Di Stefani A; Pellegrini C; Requena C; Fargnoli MC; Peris K; Cota C; Menin C; Landi MT; Nagore E
    Dermatology; 2024; 240(1):164-169. PubMed ID: 37918362
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular pathogenesis of malignant melanoma: a different perspective from the studies of melanocytic nevus and acral melanoma.
    Takata M; Murata H; Saida T
    Pigment Cell Melanoma Res; 2010 Feb; 23(1):64-71. PubMed ID: 19788535
    [TBL] [Abstract][Full Text] [Related]  

  • 23. BRAF, KIT, and NRAS Mutations of Acral Melanoma in White Patients.
    Dika E; Veronesi G; Altimari A; Riefolo M; Ravaioli GM; Piraccini BM; Lambertini M; Campione E; Gruppioni E; Fiorentino M; Melotti B; Ferracin M; Patrizi A
    Am J Clin Pathol; 2020 Apr; 153(5):664-671. PubMed ID: 32017841
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic and predictive values of oncogenic BRAF, NRAS, c-KIT and MITF in cutaneous and mucous melanoma.
    Pracht M; Mogha A; Lespagnol A; Fautrel A; Mouchet N; Le Gall F; Paumier V; Lefeuvre-Plesse C; Rioux-Leclerc N; Mosser J; Oger E; Adamski H; Galibert MD; Lesimple T
    J Eur Acad Dermatol Venereol; 2015 Aug; 29(8):1530-8. PubMed ID: 25623140
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The clinical significance of BRAF and NRAS mutations in a clinic-based metastatic melanoma cohort.
    Ekedahl H; Cirenajwis H; Harbst K; Carneiro A; Nielsen K; Olsson H; Lundgren L; Ingvar C; Jönsson G
    Br J Dermatol; 2013 Nov; 169(5):1049-55. PubMed ID: 23855428
    [TBL] [Abstract][Full Text] [Related]  

  • 26. NRAS (Q61R), BRAF (V600E) immunohistochemistry: a concomitant tool for mutation screening in melanomas.
    Uguen A; Talagas M; Costa S; Samaison L; Paule L; Alavi Z; De Braekeleer M; Le Marechal C; Marcorelles P
    Diagn Pathol; 2015 Jul; 10():121. PubMed ID: 26204954
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Distinct MAPK and PI3K pathway mutations in different melanoma types in Taiwanese individuals.
    Gao HW; Tsai WC; Perng CL; Wang WM; Chiang CP
    Eur J Dermatol; 2018 Aug; 28(4):509-518. PubMed ID: 30325319
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Assessment of clinical parameters associated with mutational status in metastatic malignant melanoma: a single-centre investigation of 141 patients.
    Schlaak M; Bajah A; Podewski T; Kreuzberg N; von Bartenwerffer W; Wardelmann E; Merkelbach-Bruse S; Büttner R; Mauch C; Kurschat P
    Br J Dermatol; 2013 Apr; 168(4):708-16. PubMed ID: 23528057
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prevalence of BRAF, NRAS and c-KIT mutations in Slovenian patients with advanced melanoma.
    Moltara ME; Novakovic S; Boc M; Bucic M; Rebersek M; Zadnik V; Ocvirk J
    Radiol Oncol; 2018 Apr; 52(3):289-295. PubMed ID: 30210039
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oncogene abnormalities in a series of primary melanomas of the sinonasal tract: NRAS mutations and cyclin D1 amplification are more frequent than KIT or BRAF mutations.
    Chraybi M; Abd Alsamad I; Copie-Bergman C; Baia M; André J; Dumaz N; Ortonne N
    Hum Pathol; 2013 Sep; 44(9):1902-11. PubMed ID: 23664541
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative analysis of BRAF, NRAS and c-KIT mutation status between tumor tissues and autologous tumor cell-lines of stage III/IV melanoma.
    Knol AC; Pandolfino MC; Vallée A; Nguyen F; Lella V; Khammari A; Denis M; Puaux AL; Dréno B
    Exp Dermatol; 2015 Jan; 24(1):70-3. PubMed ID: 25363723
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Detection of cell-free circulating BRAF
    Calbet-Llopart N; Potrony M; Tell-Martí G; Carrera C; Barreiro A; Aguilera P; Podlipnik S; Puig S; Malvehy J; Puig-Butillé JA
    Br J Dermatol; 2020 Feb; 182(2):382-389. PubMed ID: 31102256
    [TBL] [Abstract][Full Text] [Related]  

  • 33. SF3B1, NRAS, KIT, and BRAF Mutation; CD117 and cMYC Expression; and Tumoral Pigmentation in Sinonasal Melanomas: An Analysis With Newly Found Molecular Alterations and Some Population-Based Molecular Differences.
    Wroblewska JP; Mull J; Wu CL; Fujimoto M; Ogawa T; Marszalek A; Hoang MP
    Am J Surg Pathol; 2019 Feb; 43(2):168-177. PubMed ID: 30273197
    [TBL] [Abstract][Full Text] [Related]  

  • 34. KIT, NRAS and BRAF mutations in sinonasal mucosal melanoma: a study of 56 cases.
    Zebary A; Jangard M; Omholt K; Ragnarsson-Olding B; Hansson J
    Br J Cancer; 2013 Aug; 109(3):559-64. PubMed ID: 23860532
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular characterization and patient outcome of melanoma nodal metastases and an unknown primary site.
    Gos A; Jurkowska M; van Akkooi A; Robert C; Kosela-Paterczyk H; Koljenović S; Kamsukom N; Michej W; Jeziorski A; Pluta P; Verhoef C; Siedlecki JA; Eggermont AM; Rutkowski P
    Ann Surg Oncol; 2014 Dec; 21(13):4317-23. PubMed ID: 24866436
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mutation scanning of BRAF, NRAS, KIT, and GNAQ/GNA11 in oral mucosal melanoma: a study of 57 cases.
    Lyu J; Wu Y; Li C; Wang R; Song H; Ren G; Guo W
    J Oral Pathol Med; 2016 Apr; 45(4):295-301. PubMed ID: 26399561
    [TBL] [Abstract][Full Text] [Related]  

  • 37. BRAF, KIT, NRAS, GNAQ and GNA11 mutation analysis in cutaneous melanomas in Turkish population.
    Yilmaz I; Gamsizkan M; Kucukodaci Z; Berber U; Demirel D; Haholu A; Narli G
    Indian J Pathol Microbiol; 2015; 58(3):279-84. PubMed ID: 26275246
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clonal architectures and driver mutations in metastatic melanomas.
    Ding L; Kim M; Kanchi KL; Dees ND; Lu C; Griffith M; Fenstermacher D; Sung H; Miller CA; Goetz B; Wendl MC; Griffith O; Cornelius LA; Linette GP; McMichael JF; Sondak VK; Fields RC; Ley TJ; Mulé JJ; Wilson RK; Weber JS
    PLoS One; 2014; 9(11):e111153. PubMed ID: 25393105
    [TBL] [Abstract][Full Text] [Related]  

  • 39. BRAF, NRAS and HRAS mutations in spitzoid tumours and their possible pathogenetic significance.
    Da Forno PD; Pringle JH; Fletcher A; Bamford M; Su L; Potter L; Saldanha G
    Br J Dermatol; 2009 Aug; 161(2):364-72. PubMed ID: 19438459
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Human malignant melanoma: detection of BRAF- and c-kit-activating mutations by high-resolution amplicon melting analysis.
    Willmore-Payne C; Holden JA; Tripp S; Layfield LJ
    Hum Pathol; 2005 May; 36(5):486-93. PubMed ID: 15948115
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.